|Ms. Yi-Li Li||Exec. Director||146k||N/A||N/A|
|Weitang Hong||Fin. Mang. and Director||45k||N/A||N/A|
|Ms. Yi-Li Lee||Deputy Chairperson & Pres||N/A||N/A||N/A|
|Chih Yuan Huang||Financial & Accounting Officer||N/A||N/A||N/A|
|Mr. Zhenggang Chen||Chief R&D Officer||N/A||N/A||N/A|
AmCad BioMed Corporation develops computer-assisted detection and diagnosis (CAD) software devices primarily in Taiwan. Its products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO, a solution for obstructive sleep apnea detection. The company is also developing AmCAD-CA, a software designed for analyzing digital cytological images; AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals. The company was founded in 2008 and is based in Taipei City, Taiwan.
AmCad BioMed Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.